Why I'd Consider These Top Healthcare Stocks for a $10,000 Long-Term Investment
Knight Therapeutics Inc. Ranks on The Globe and Mail's Sixth-annual Women Lead Here Benchmark of Executive Gender Diversity
Knight Therapeutics Inc: AUDITED ANNUAL FINANCIAL STATEMENTS FR
Knight Therapeutics Inc: MDA FR
Knight Therapeutics Inc: ANNUAL REPORT FR
Knight Therapeutics Inc: ANNUAL REPORT EN
Express News | Knight Therapeutics Announces Launch of Minjuvi® (Tafasitamab) in Mexico
Knight Therapeutics Announces Launch of Minjuvi (Tafasitamab) in Mexico
G2S2 Capital Sells 50,000 Shares in Knight Therapeutics
G2S2 CAPITAL INC. FILES EARLY WARNING REPORT FOR INVESTMENT IN KNIGHT THERAPEUTICS INC.
3 Top Healthcare Sector Stocks for Canadian Investors in 2025
Earnings Call Summary | KNIGHT THERAPEUTICS INC(KHTRF.US) Q4 2024 Earnings Conference
Knight Therapeutics Swings to Q4 Profit, Revenue Advances
Knight Therapeutics Inc: MDA EN
Knight Therapeutics Inc: AUDITED ANNUAL FINANCIAL STATEMENTS EN
Earnings Flash (GUD.TO) Knight Therapeutics Posts Q4 Revenues C$96.864 Million
Notice of Knight Therapeutics' Fourth Quarter and Year End 2024 Results Conference Call
Knight Therapeutics Inc. Is Maintained at Outperform by RBC Capital
Knight Therapeutics Price Target Raised at RBC, Raymond James
Knight Therapeutics Brief: In Addition, Knight May Pay Future Contingent Payments of up to US$15 Million Upon Achieving Certain Sales Milestones